Document text
Principal Investigator: Linda L Chao
Organization: VETERANS AFFAIRS MED CTR SAN FRANCISCO
Fiscal Year: 2024
Funding agency: Veterans Affairs
Nearly 30 years after the end of the 1991 Persian Gulf War (GW), an estimated 25-32% of GW veterans still
suffer from Gulf War illness (GWI),1 the term used to describe the symptoms that have plagued many GW
veterans since their return from deployment. Although symptoms may vary from veteran to veteran, GWI
typically includes some combination of fatigue, pain, cognitive/mood dysfunction, sleep disturbances, and
autonomic disturbances such as gastrointestinal (GI), urinary, and sexual dysfunction. Epidemiological data
suggest a possible link between chemical exposures and Parkinson’s disease (PD).4 Although GW military
personnel were exposed to multiple, potentially hazardous chemicals in the Persian Gulf theater, to date there
has been no reliable data on the incidence or prevalence of PD among GW veterans.1 However, it is
noteworthy that many of the symptoms of GWI are similar to non-motor symptoms (NMS) in PD,7 which can
predominate years to decades prior to clinical diagnosis.9 For example, some common NMS in PD include
fatigue, pain, autonomic disturbances, such as GI, urinary, and sexual dysfunction, sleep disturbances,
anxiety, depression, and cognitive dysfunction such as difficulties with memory, concentration, and word
finding. We have preliminary evidence of positive associations between GW veterans’ self-reported frequency
of exposures to deployment-related chemicals and GWI symptoms similar to PD’s NMS. We have also found
an inverse relationship between GW veterans’ self-reported frequency of wearing pesticide-treated uniforms
and measures of manual dexterity. Finally, we have preliminary evidence of negative associations between the
veterans’ self-reported frequency of exposures to GW-related chemicals and basal ganglia volume and basal
ganglia N-acetylaspartate (NAA), a marker of neuronal integrity.11 Because NMS and significant neuronal loss
in the substantia nigra are two characteristics that have been repeatedly noted in individuals who eventually
develop clinical PD,9 based on these preliminary findings, we hypothesize that GW veterans with excessive
exposures to deployment-related chemicals have prodromal PD. While there is presently no cure or disease-
modifying treatment that halts or slows the progression PD, the precocious diagnosis of PD in GW veterans
with high exposures to GW-related toxicants would facilitate the targeted delivery of neuroprotective therapies
when they eventually do become available. Furthermore, these GW veterans may be counseled to adopt
lifestyle changes, such as increasing physical activity, which have been associated with lowering the risk of
PD.13 The proposed four-year study will enroll 140 GW veterans with high levels of exposure to deployment-
related chemicals (e.g., GW pesticide applicators). We will obtain clinical and behavioral measures and in vivo
ultra-high field (7 Tesla) and 3 Tesla magnetic resonance imaging (MRI) measures of iron, neuromelanin, and
free water in the substantia nigra. We propose three specific aims that will: (1) evaluate GW veterans using the
International Parkinson and Movement Disorder Society (MDS) research criteria for prodromal PD;14 (2)
examine the association between the veterans’ self-reported frequency of exposures to GW deployment-
related chemicals and 7 Tesla measures of iron and neuromelanin and the veterans’ probability of prodromal
PD according to the MDS research criteria; and (3) compare 3 Tesla measures of free water in the substantia
nigra and scores from various NMS scales from the Parkinson's Progression Markers Initiative (PPMI)15
dataset in GW veterans with age- and gender-matched healthy controls, PD patients, and subjects with
prodromal PD from the PPMI cohort. The proposed experiments are timely and important because it is
expected to provide much needed information on the long-term consequences of GWI in the context of aging
and neurodegenerative diseases, particularly PD.
Terms: <Adopted><Age><Aging><Anxiety><Armed Forces Personnel><Basal Ganglia><Basal Nuclei><Behavioral><Characteristics><Chemical Exposure><Chemicals><Clinical><Cognitive><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Counseling><DA Neuron><Data><Data Set><Degenerative Neurologic Disorders><Department of Defense><Diagnosis><Disease><Disorder><Disturbance in cognition><Dopamine neuron><Dyskinesia Syndromes><Enrollment><Environmental Exposure><Epidemiologic Research><Epidemiologic Studies><Epidemiological Studies><Epidemiological data><Epidemiology><Epidemiology Research><Epidemiology data><Exposure to><Fatigue><Fe element><Frequencies><GW veteran><Gender><Gulf War><Gulf War Illness><Gulf War Syndrome><Gulf War veteran><HAZMAT><Hazardous Chemicals><Hazardous Materials><Hazardous Substances><Health><History><Human Resources><Hydrogen Oxide><Image><Impaired cognition><Incidence><Individual><International><Investigation><Iron><Kansas><Lack of Energy><Life Style><Lifestyle><Link><MDS-UPDRS><MDS-Unified Parkinson's Disease Rating Scale><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance><Magnetic Resonance Imaging><Manpower><Manuals><Measures><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Memory><Mental Depression><Military><Military Personnel><Moods><Movement Disorder Society Unified Parkinson's Disease Rating Scale><Movement Disorder Syndromes><Movement Disorders><N-acetyl aspartate><N-acetyl-L-aspartate><N-acetylaspartate><NMR Imaging><NMR Tomography><Nerve Cells><Nerve Degeneration><Nerve Unit><Nervous System Degenerative Diseases><Neural Cell><Neural Degenerative Diseases><Neural degenerative Disorders><Neurocyte><Neurodegenerative Diseases><Neurodegenerative Disorders><Neurologic Degenerative Conditions><Neuron Degeneration><Neurons><Nuclear Magnetic Resonance Imaging><Operation Desert Shield><Operation Desert Storm><Pain><Painful><Paralysis Agitans><Parkinson><Parkinson Disease><Participant><Patient Self-Report><Patients><Persian Gulf><Persian Gulf Syndrome><Pesticides><Physical activity><Pigments><Prevalence><Primary Parkinsonism><Probability><Questionnaires><Recording of previous events><Research><Risk><Self-Report><Severities><Sex Disorders><Sexual Dysfunction><Sleep disturbances><Societies><Substantia Nigra><Substantia nigra structure><Symptoms><Testing><Toxicant exposure><UPDRS><Unified Parkinson's Disease Rating Scale><Veterans><War><Water><Zeugmatography><aberrant sleep><affective disturbance><ages><associated symptom><behavior measurement><behavioral measure><behavioral measurement><chronic symptom><clinical diagnosis><co-morbid symptom><co-occuring symptom><cognitive dysfunction><cognitive loss><cohort><comorbid symptom><concurrent symptom><cooccuring symptom><degenerative diseases of motor and sensory neurons><degenerative neurological diseases><depression><dexterity><disrupted sleep><disturbance in affect><disturbed sleep><dopaminergic neuron><enroll><epidemiologic><epidemiologic data><epidemiologic investigation><epidemiological><epidemiology study><experience><experiment><experimental research><experimental study><experiments><gastrointestinal><haz mat><histories><imaging><impaired sleep><in vivo><irregular sleep><military population><mood alteration><mood and affect disturbance><mood disturbance><mood dysfunction><motor symptom><nerve cell death><nerve cell loss><neural degeneration><neurodegeneration><neurodegenerative><neurodegenerative illness><neurological degeneration><neuromelanin><neuron cell death><neuron cell loss><neuron death><neuron loss><neuronal><neuronal cell death><neuronal cell loss><neuronal death><neuronal degeneration><neuronal loss><neuroprotection><neuroprotective><non-motor symptom><nonmotor symptom><persistent symptom><personnel><pigment><progression biomarker><progression marker><site targeted delivery><sleep disruption><sleep dysregulation><symptom association><symptom comorbidity><symptomatology><targeted delivery><toxic exposure><toxicant><urinary>